David Englert
Chief Tech/Sci/R&D Officer at Xceed Molecular Corp.
Profile
David Englert is currently the Vice President-Technology Development at Xceed Molecular Corp.
He previously worked as the Director-Applied Research at Packard BioScience Co., a Researcher at Harvard University, a Researcher at The State University of New York, and a Researcher at Pharmacia LKB Biotechnology, Inc. Dr. Englert holds a doctorate degree from The State University of New York.
David Englert active positions
| Companies | Position | Start |
|---|---|---|
Xceed Molecular Corp.
 Xceed Molecular Corp. Medical SpecialtiesHealth Technology Xceed Molecular Corporation is a molecular diagnostic company dedicated to commercializing a platform for automated gene expression analysis and developing proprietary clinical research assays and custom arrays. They develop tools and content aimed at accelerating the current market trend towards 'translational medicine', and bridging the gap from gene signature validation to clinical diagnostics. The Ziplex Automated Workstation is the first integrated and fully automated hybridization system for multiplex gene expression signatures. Their integrated solution - the Ziplex System - features this innovative instrument platform and focused-content TipChip arrays and reagents to perform highly multiplexed molecular assays with superior accuracy, reproducibility, speed and scalability. The Ziplex System is designed to provide the ease-of-use in assay automation and analytics that is required to successfully translate gene expression analysis from research use into routine practice. Xceed complements the Ziplex platform by offering Gene Expression Services and Assay Development Services. | Chief Tech/Sci/R&D Officer | - |
Former positions of David Englert
| Companies | Position | End |
|---|---|---|
| The State University of New York | Corporate Officer/Principal | - |
| Pharmacia LKB Biotechnology, Inc. | Corporate Officer/Principal | - |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Packard BioScience Co.
 Packard BioScience Co. Medical SpecialtiesHealth Technology On July 13, 2001, the company entered into a merger agreement with PerkinElmer, Inc. Pursuant to the merger agreement, the company will become a subsidiary of PerkinElmer and each outstanding share of the company's common stock will be converted into 0.311 of a share of PerkinElmer common stock | Corporate Officer/Principal | - |
Training of David Englert
| The State University of New York | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Xceed Molecular Corp.
Xceed Molecular Corp. Medical SpecialtiesHealth Technology Xceed Molecular Corporation is a molecular diagnostic company dedicated to commercializing a platform for automated gene expression analysis and developing proprietary clinical research assays and custom arrays. They develop tools and content aimed at accelerating the current market trend towards 'translational medicine', and bridging the gap from gene signature validation to clinical diagnostics. The Ziplex Automated Workstation is the first integrated and fully automated hybridization system for multiplex gene expression signatures. Their integrated solution - the Ziplex System - features this innovative instrument platform and focused-content TipChip arrays and reagents to perform highly multiplexed molecular assays with superior accuracy, reproducibility, speed and scalability. The Ziplex System is designed to provide the ease-of-use in assay automation and analytics that is required to successfully translate gene expression analysis from research use into routine practice. Xceed complements the Ziplex platform by offering Gene Expression Services and Assay Development Services. | Health Technology |
Packard BioScience Co.
Packard BioScience Co. Medical SpecialtiesHealth Technology On July 13, 2001, the company entered into a merger agreement with PerkinElmer, Inc. Pursuant to the merger agreement, the company will become a subsidiary of PerkinElmer and each outstanding share of the company's common stock will be converted into 0.311 of a share of PerkinElmer common stock | Health Technology |
| Pharmacia LKB Biotechnology, Inc. |
- Stock Market
- Insiders
- David Englert
